Table 2.
Eight studies reporting the treatment outcomes of lacrimal sac tumor.
| Reference | PE | TM | RT | FT (m) | MR | RR | DMR |
|---|---|---|---|---|---|---|---|
| Ni et al.12 | 67 | S, R, C | 67/67 | / | 31.3% | 13.4% | / |
| Parmaret al.13 | 15 | S, R, C | 9/15 | 2–204 | 13.3% | 20% | 20% |
| Valenzuela et al.14 | 11 | S, R | 4/11 | 6–84 | 18.2% | 0 | 27.3% |
| Kang et al.15 | 10 | S, R | 4/10 | 3–239 | 20% | 10% | 20% |
| Montalbanet al.1 | 7 | S, R, I | 5/7 | 6–204 | 14% | 28.6% | 0 |
| Skinner et al.16a | 13 | S, R, C | 10/13 | 3–460 | 32.6% | 39.1% | 39.1% |
| Alabiadet al.17 | 14 | S, R | 9/14 | 9–149 | 14% | 14% | 7% |
| EI-Sawyet al.18 | 14 | S, R, C | 12/14 | 6–96 | 21.4% | 28.6% | 21.4% |
| Song et al. | 17 | R, C | 17/17 | 7–106 | 17.6% | 5.9% | 11.8% |
C, chemotherapy; DMR, distant metastasis rate; FT(m), follow-up time (months); I, immunotherapy; MR, mortality rate; PE, patients evaluated; R, radiotherapy; RR, recurrent rate; RT, radiation therapy; S, surgery; TM, treatment modality.
a
the data in lacrimalsac/duct referring to the 46 cases with tumors of the lacrimal apparatus